Drug Regulatory Authority of Pakistan (DRAP) has approved China’s CanSinoBIO’s Coronavirus vaccine, Ad5-nCoV, for marketing through public and private sectors.
According to the official statement, DRAP has decided to grant marketing approval to Ad5-nCoV after receiving positive results of the vaccine’s multination phase-III clinical trials from the Ministry of Health.
CanSinoBIO’s vaccine is 65% effective at preventing symptomatic cases and 91% effective at preventing severe infection.
As for the Pakistani subset, the vaccine is offering 75% protection against symptomatic cases and 100% protection against severe infection.
Besides, no serious safety concerns and side-effects of the CanSinoBIO vaccine have been reported during the multination clinical trials.
Pakistan has already booked enough CanSino’s COVID-19 vaccine doses to vaccinate 20 million citizens.
CanSino’s vaccine is the third Chinese vaccine to hit the markets. Sinovac and Sinopharm have developed the other two and both have been approved for use in numerous countries.